Exchange: NASDAQ·Updated 08:17 PM EDT

CLDX News

News
all
press releases
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.
Stocktwits
More News
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Zacks
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) PR Newswire NEW YORK, Aug. 24, 2026 NEW YORK, Aug...
PR Newswire
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Zacks
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?
Celldex announced that its experimental drug barzolvolimab missed key goals in a mid-stage study for prurigo nodularis.
Stocktwits
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval...
Yahoo! Finance: News
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.